Table 3 IgE percentage reduction during VIT related to field sting
From: Determinants of venom-specific IgE antibody concentration during long-term wasp venom immunotherapy
YJ-IgE levels (kUA/L) | Group | Mean ± SD | Min | Max | Mean percentage reduction (%) |
|---|---|---|---|---|---|
CAP0–CAP3 | NoS | 3.81 ± 5.13 | 0.01 | 27.59 | 48.2 |
SP 0–3 | 2.61 ± 3.53 | 0.00 | 21.22 | 30.7 | |
SP 3–5 | 4.75 ± 5.32 | 0.00 | 25.07 | 53.7 | |
CAP3–CAP5 | NoS | 0.97 ± 1.60 | 0.00 | 11.97 | 37.1 |
SP 0–3 | 2.68 ± 4.13 | 0.00 | 20.97 | 50.3 | |
SP 3–5 | 0.82 ± 1.03 | 0.00 | 6.40 | 17.0 | |
CAP0–CAP5 | NoS | 4.39 ± 5.48 | 0.00 | 27.54 | 68.6 |
SP 0–3 | 5.15 ± 6.16 | 0.00 | 30.87 | 70.5 | |
SP 3–5 | 5.24 ± 5.55 | 0.12 | 25.30 | 57.7 |